The Carlyle Group will acquire Abingworth, one of biotech’s oldest venture capital groups, it announced Monday. The financial terms of the deal, which will close later this year, were not disclosed.
Abingworth, which just raised about $1 billion last year for two new funds, was ranked 12th in STAT’s 2020 ranking of 17 biotech venture investors; the firm was not included in the 2021 rankings.
Abingworth isn’t the first firm to be bought up by a much larger private equity investor. In 2018, Blackstone bought Clarus, creating Blackstone Life Sciences.
Create a display name to comment
This name will appear with your comment